Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Oct 8;2008(4):CD005644.
doi: 10.1002/14651858.CD005644.pub2.

Antimotility agents for chronic diarrhoea in people with HIV/AIDS

Chukwuemeka E Nwachukwu  1 , Joseph U Okebe
Affiliations

Antimotility agents for chronic diarrhoea in people with HIV/AIDS

Chukwuemeka E Nwachukwu et al. Cochrane Database Syst Rev. .

Abstract

Background: AIDS-related diarrhoea is a common cause of morbidity and mortality in HIV positive individuals, especially in the sub-Saharan Africa where 70% of deaths from HIV occur. It often compromises quality of life both in those receiving antiretroviral therapy (ART) and the ART naive. Empirical antidiarrhoeal treatment may be required in about 50% of cases which are non-pathogenic or idiopathic and in cases resulting from antiretroviral therapy. Antimotility agents (Loperamide, Diphenoxylate, Codeine) and adsorbents (Bismuth Subsalicylate, Kaolin/Pectin, Attapulgite) are readily available, and have been found to be useful in this condition and so, are often used. Antimotilitics are opioids, decreasing stool output by reducing bowel activity thereby increasing fecal transit time in the gut, promoting fluid and electrolyte retention while adsorbents act by binding to fluids, toxins and other substances to improve stool consistency and eliminate the toxins. Due to its potential impact on the management of chronic diarrhoea in persons with HIV/AIDS, we reviewed the effectiveness of antimotility agents in controlling chronic diarrhoea in immunocompromised states caused by HIV/AIDS.

Objectives: To assess the effectiveness of antimotility agents in controlling chronic diarrhoea in people with HIV/AIDS.

Search strategy: We searched Medline, EMBASE, the Cochrane Controlled Trials Register, the Cochrane HIV/AIDS Register and AIDSearch databases in November 2006. We also contacted WHO, CDC, pharmaceutical companies and experts in the field for information on previous or on-going trials and checked reference list from retrieved studies, irrespective of language and publication status.

Selection criteria: Randomised controlled trials comparing an antimotility agent or an adsorbent with another antimotility agent, placebo, an adsorbent or no treatment in children and adults diagnosed with HIV and presenting with diarrhoea of three or more weeks duration.

Data collection and analysis: Two authors independently undertook study selection and examined full articles of potentially eligible studies.

Main results: One trial was found assessing the use of an adsorbent (attapulgite) compared to a placebo for chronic diarrhoea in people with HIV/AIDS. It included 91 adults (Aged 18 to 60), diagnosed with AIDS and experiencing diarrhoea for at least 7 days. There was no evidence that attapulgite is superior to placebo in controlling diarrhoea by reducing stool frequency and normalising stool consistency on days 1 (0.34 (95% CI 0.01 - 8.15)), 3 (1.35 (95% CI 0.51 - 3.62)) and 5 (1.74 (95% CI 0.89 - 3.38)). This was a small trial and may not have had enough power to show evidence of effects. Five deaths were reported which was not classified according to the arms of the study.Studies assessing the use of antimotility agents were not found.

Authors' conclusions: This review highlights the absence of evidence for the use of antimotility agents and adsorbents in controlling diarrhoea in people with HIV/AIDS. While no trials assessing the use of Antimotilitics were found, the retrieved study showed that attapulgite was not better than placebo in controlling diarrhoea in HIV/AIDS patients . For optimum patient care, these agents can still be used, with greater emphasis placed on adjunct therapies like massive fluid replacement while evidence for practice is awaited from further studies and reviews.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1.1
1.1. Analysis
Comparison 1 Treatment with an adsorbent versus placebo, Outcome 1 Comparison of stool consistency with Attapulgite versus Placebo.
1.2
1.2. Analysis
Comparison 1 Treatment with an adsorbent versus placebo, Outcome 2 Comparison of stool frequency with Attapulgite versus Placebo.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD005644

References

References to studies included in this review

Ilboudo 1997 {published data only}
    1. Ilboudo D, Kadio A, Monny L, Mpele P, Ndri‐Yoman T, Vohito MD. Therapeutic effect of mormoiron attapulgite in diarrhoea with AIDS [Effet therapeutique de l'attapulgite de mormoiron active dans la diarrhee liee au syndrome d'immuno‐deficience acquise (SIDA)]. Medecine d'Afrique Noire 1997;44(5):307‐12.

References to studies excluded from this review

Compean 1994 {published data only}
    1. Compean DG, Jimenez JR, Garza FG, Saenz C, Maldonado H, Barragan RF, et al. Octreotide therapy of large‐refractory AIDS‐associated diarrhea: a randomised controlled trial. AIDS 1994;8:1563‐7. - PubMed

Additional references

Abubakar 2007
    1. Abubakar I, Aliyu SH, Arumugam C, Hunter PR, Usman NK. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database of Systematic Reviews 2007, Issue 1. [Art. No.: CD004932. DOI: 10.1002/14651858.CD004932.] - PMC - PubMed
Adelman 1996
    1. Adelman RD, Solhang MJ. Fluid therapy. In: Nelson WD, Behrman RE, Kliegman RM, Arvin AM editor(s). Nelson Textbook of Paediatrics. 15. Philadelphia: W. B. Saunders, 1996.
Anastasi 2000
    1. Anastasi JK, Capili B. HIV and diarrhea in the era of HAART: 1998 New York state hospitalisations. American Journal of Infections Control 2000;28:262‐6. - PubMed
Anastasi 2003
    1. Anastasi JK, McMahon DJ. Testing strategies to reduce diarrhea in persons with HIV using traditional Chinese medicine: acupuncture and moxibustion. The Journal of the Association of Nurses in AIDS Care 2003;14(3):28‐40. - PubMed
Armon 2001
    1. Armon K, Stephenson T, MacFaul R, Eccleston P, Werneke U. An evidence and concensus based guideline for acute diarrhoea management. Archives of Diseases in Childhood 2001;85:132‐42. - PMC - PubMed
Brawner‐Caluag 1993
    1. Brawner‐Caluag J. Mendoza RM, Valencia CI, Galang RM. A phase IV study of Loperamide hydrochloride in acute non‐dysenteric diarrhea among hospitalized adult Filipino patients. Philipines Journal of Internal Medicine 1993;31:273‐84.
Carcamo 2005
    1. Carcamo C, Hooton T, Wener MH, Weiss NS, Gilman R, Arevalo J, et al. Etiologies and manifestations of persistent diarrhoea in adults with HIV‐1 infection: a case‐control study in Lima, Peru. Journal of Infectious Diseases 2005;191(1):11‐9. - PubMed
Carr 2000
    1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423‐30. - PubMed
Cohen 1999
    1. Cohen MR, Mitchel TF, Bacchetti P, Child C, Crawford S, Gaeddert A, et al. Use of a Chinese herbal medicine for treatment of HIV‐associated pathogen‐negative diarrhea. Integrative Medicine 1999;2:79‐84. - PubMed
Deschamps 2000
    1. Deschamps MM, Fitzgerald DW, Pape JE, Johnson WD. HIV Infection in Haiti: natural history and disease progress. AIDS 2000;14:2515‐21. - PubMed
Dryden 1988
    1. Dryden MS, Shanson DC. The microbial causes of diarrhoea in patients infected with the human immunodeficiency virus. Journal of Infections 1988;17(2):107‐14. - PubMed
Dumitrascu 2004
    1. Dumitrascu DL, Stanculete M, Mitrea I, Dumitrascu DM, Farcas A. The effect of two antidiarrhoeal drugs on the psychosocial adjustment to illness in chronic functional diarrhoea. Romanian Journal of Internal Medicine 2004;42(1):191‐7. - PubMed
DuPont 1992
    1. DuPont HL, Cooperstock M, Corrado ML, Fekety R, Murray DM. Evaluation of new anti infective drugs for the treatment of acute infectious diarrhea. Clinical Infectious Diseases 1992;15 Suppl 1:S228‐35. - PubMed
DuPont 1993
    1. DuPont HL. Diarrhoeal diseases: current concepts and future challenges. Antimicrobial therapy and prophylaxis. Transactions of the Royal Society of Tropical Medicine and Hygiene 1993;87 Suppl3:31‐4. - PubMed
Edwards 1990
    1. Edwards P, Wodak A, Cooper DA, Thompson IL, Penny R. The gastrointestinal manifestations of AIDS. Australian and New Zealand Journal of Medicine 1990;20(2):141‐8. - PubMed
Foudraine 1998
    1. Foudraine NA, Weverling GJ, Gool T, Roos MT, Wolf F, Koopmans PP, et al. Improvement of chronic diarhoea in patients with advanced HIV‐1 infection during potent antiretroviral therapy. AIDS 1998;12(1):35‐41. - PubMed
Gassama 2001
    1. Gassama A, Sow PS, Fall F, Camara P, Gueye‐N'diaye A, Seng R, et al. Ordinary and opportunistic enteropathogens associated with diarrhea in Senegalese adults in relation to human immunodeficiency virus serostatus. International Journal of Infectious Diseases 2001;5(4):192‐8. - PMC - PubMed
Greenwood 2004
    1. Greenwood‐Van Meerveld B, Gardner CJ, Little PJ, Hicks GA, Dehaven‐Hudkins DL. Preclinical studies of opoid antagonists on gastrointestinal function. Neurogastroenterology and Motility 2004;16 Suppl 2:46‐53. - PubMed
Guarino 2004
    1. Guarino A, Bruzzese E, Marco G, Buccigrossi V. Management of gastrointestinal disorders in children with HIV infection. Paediatric Drugs 2004;6(6):347‐62. - PubMed
Guest 2004
    1. Guest JL, Ruffin C, Tschampa JM, DeSilva KE, Rimland D. Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir‐ritonavir or nelfinavir. Pharmacotherapy. 2004;24(6):727‐35. - PubMed
Jamjian 2000
    1. Jamjian MC, Mullin S, Ries KM, Spruance SL. Managing the adverse effects of antiretroviral therapy. hivnewsline.com 2000 (assessed 29 september 2005); Vol. 6(4).
Kadapu 2002
    1. Kadapu KK, Nagaraja MV, Rao PV, Shasty BA. Azithromycin as treatment for cryptosporidiosis in human immunodeficiency virus disease. Journal of Postgraduate Medicine 2002;48:179‐81. - PubMed
Kaplan 2004
    1. Kaplan JE. Diagnosis, Treatment and Prevention of selected common HIV‐related opportunistic infections in the Carribean region. Topics in HIV Medicine Dec.2004/Jan 2005;12(5):136‐41. - PubMed
Katabira 1999
    1. Katabira ET. Epidemiology and management of diarrheal diseases in HIV‐infected persons. International Journal of Infectious Diseases 1999;3:164‐7. - PubMed
Krain 2005
    1. Krain A, Fitzgerald DW. HIV antiretroviral therapy in resource‐limited settings: experiences from Haiti. Current HIV/AIDS Reports 2005;2(2):98‐104. - PubMed
Liu 2005
    1. Liu JP, Manheimer E, Yang M. Herbal medicines for treating HIV infection and AIDS. Cochrane Database of Systematic Reviews 2005, Issue 3. - PMC - PubMed
Logie 2004
    1. Logie DE. Reframing the HIV/AIDS debate in developing countries III: an effective, equitable response. Rural and Remote Health 4 (online) (http://rrh.deakin.edu.au) 2004 (accessed on 16 september 2005). - PubMed
Lutge 2005
    1. Lutge E. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS. Cochrane Database of Systematic Reviews 2005, Issue 2. [Art. No.: CD005175. DOI: 10.1002/14651858.CD005175.pub2.] - PMC - PubMed
McQuain 2004
    1. McQuain KR. Drugs used in Gatrointestinal Diseases. In: Katzung BG editor(s). Basic & Clinical Pharmacology. 9th Edition. McGraw Hill, 2004:1034‐60.
Moyle 1998
    1. Moyle GJ, Youle M, Higgs C, Monaghan J, Prince W, Chapman S, et al. Safety, pharmacokinetics and antiretroviral activity of the potent, specific human immunodeficiency virus protease inhibitor nelfinavir: results of a phase I/II trial and extended follow‐up in patients infected with human immunodeficiency virus. Journal of Clinical Pharmacology 1998;38:736‐43. - PubMed
Mwachari 1998
    1. Mwachari C, Batchelor BI, Paul J, Waiyaki PG, Gilks CF. Chronic diarrhoea among HIV‐infected adult patients in Nairobi, Kenya. The Journal of Infection 1998;37(1):48‐53. - PMC - PubMed
O'Brien 2003
    1. O'Brien ME, Clark RA, Besch CL, Myers L, Kissinger P. Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort. Journal of Acquired Immune Deficiency Syndrome 2003;34(4):407‐14. - PubMed
O'Dell 1995
    1. O'Dell MW, Lubeck DP, O'Driscoll, Matsuno S. Validity of the Karnofsky Performance Status in an HIV‐infected sample. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;10(3):350‐7. - PubMed
Pape 1994
    1. Pape JW, Verdier RI, Boncy M, BoncyJ, Johnson WD. Cyclospora Infection in adults infected with HIV: Clinical manifestations, treatment, and prophylaxis. Annals of Internal Medicine 1994;121:654‐7. - PubMed
Schiller 1982
    1. Schiller LR, Davis GR, Santa Ana CA, Morawski SG, Fordtran JS. Studies of mechanism of the antidiarrhoeal effect of codeine. Journal of Clinical Investigations 1982;70(5):999‐1008. - PMC - PubMed
Schumacher 2004
    1. Schumacher MA, Basbaun AI, Way WL. Opioid Analgesics & Antagonists. In: Katzung BG editor(s). Basic and Clinical Pharmacology. 7th Edition. McGraw Hill, 2004:497‐516.
Sherman 2000
    1. Sherman DS, Fish DN. Management of protease inhibitor‐associated diarrhoea. Clinical Infectious Diseases 2000;30(6):908‐14. - PubMed
Silverberg 2004
    1. Silverberg MJ, Gore ME, French AL, Gandhi M, Glesby MJ, Kovacs A, et al. Prevalence of clinical symptoms associated with highly active antiretroviral therapy in the Women's Interangency HIV Study. Clinical Infectious Diseases 2004;39(5):717‐24. - PMC - PubMed
Turner 2004
    1. Turner MJ, Angel JB, Woodend K, Giguere P. The efficacy of calcium carbonate in the treatment of protease inhibitor‐induced persistent diarrhea in HIV‐infected patients. HIV Clinical Trials 2004;5(1):19‐24. - PubMed
UNAIDS 2004
    1. 2004 report on the global AIDS epidemic. Joint United Nations Programme on HIV/AIDS. Geneva, 2004.
UNAIDS 2006
    1. UNAIDS. 2006 Report on the Global AIDS Epidemic. Geneva, 2006:16‐43.
Walter‐Smith 1993
    1. Walter‐smith JA. Diarrhoeal diseases: current concepts and future challenges. Malnutrition and infection. Transactions of the Royal Society of Tropical Medicine and Hydiene 1993;87,Suppl 3:13‐5. - PubMed
Wang 2005
    1. Wang H, Shieh M, Liao K. A blind, randomised comparison of racecadotril and loperamide for stopping acute diarrhea in adults. World Journal of Gastroenterology 2005;11(10):1540‐3. - PMC - PubMed
WHO 1991
    1. Guidelines for the clinical management of HIV infections in adults. WHO/GPA. Geneva, 1991.
WHO 2005
    1. Interim WHO clinical staging of HIV/AIDS and HIV/AIDS case definitions for surveillance. WHO/HIV/2005.02 2005.
WHO 2008
    1. WHO. World Health Statistics. Geneva, 2008:13‐4.

Publication types

MeSH terms

LinkOut - more resources